Company profile
RedHill Biopharma Ltd.
NASDAQ:RDHLBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OPAGANIB | phase2_3 | — | 4 | completed, terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (18)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03377179 | phase2 | completed | 2018-03-07 | 2022-06-21 | RedHill Biopharma Limited | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma |
| NCT04414618 | phase2 | completed | 2020-07-02 | 2020-11-26 | RedHill Biopharma Limited | A Study of Opaganib in Coronavirus Disease 2019 Pneumonia |
| NCT02757326 | phase1_2 | terminated | 2016-12-13 | 2019-05-01 | RedHill Biopharma Limited | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma |
| NCT01488513 | phase1 | completed | 2011-08-01 | 2014-08-01 | RedHill Biopharma Limited | ABC294640 in Treating Patients With Advanced Solid Tumors |
| NCT02246439 | phase3 | completed | 2014-12-08 | 2017-02-13 | RedHill Biopharma Limited | BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis |
FDA applications (0)
No records yet.